These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38133181)

  • 21. Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies.
    Nsaka M; Scheffler A; Wurthmann S; Schenk H; Kleinschnitz C; Glas M; Holle D
    Brain Behav; 2022 Jul; 12(7):e2662. PubMed ID: 35687795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA.
    Torres-Ferrus M; Gallardo VJ; Alpuente A; Pozo-Rosich P
    J Headache Pain; 2020 Jul; 21(1):88. PubMed ID: 32652924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 2022 Taiwan Guidelines for Preventive Treatment of Migraine.
    Wu JW; Yang CP;
    Acta Neurol Taiwan; 2022 Sep; 31(3)():164-202. PubMed ID: 36089629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine.
    Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
    Eur J Neurol; 2022 May; 29(5):1505-1513. PubMed ID: 35098620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study.
    Iannone LF; Burgalassi A; Vigani G; Tabasso G; De Cesaris F; Chiarugi A; Geppetti P
    Cephalalgia; 2023 Apr; 43(4):3331024231160519. PubMed ID: 36918752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of prophylactic drug therapies and anti-calcitonin peptide-related monoclonal antibodies on subjective sleep quality: An Italian multicenter study.
    Viticchi G; Di Stefano V; Altamura C; Falsetti L; Torrente A; Brunelli N; Salvemini S; Alonge P; Bartolini M; Di Felice C; Adragna MS; Moroncini G; Vernieri F; Brighina F; Silvestrini M
    Sleep Med; 2024 May; 117():87-94. PubMed ID: 38518587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany.
    Hong JB; Lange KS; Fitzek M; Overeem LH; Triller P; Siebert A; Reuter U; Raffaelli B
    J Headache Pain; 2023 Oct; 24(1):144. PubMed ID: 37899428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine.
    Argyriou AA; Dermitzakis EV; Xiromerisiou G; Vikelis M
    Toxins (Basel); 2022 Dec; 14(12):. PubMed ID: 36548744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients.
    Muñoz-Vendrell A; Campoy S; Caronna E; Alpuente A; Torres-Ferrus M; Nieves Castellanos C; Olivier M; Campdelacreu J; Prat J; Camiña Muñiz J; Molina Martínez FJ; Mínguez-Olaondo A; Ruibal Salgado M; Santos Lasaosa S; Navarro Pérez MP; Morollón N; López Bravo A; Cano Sánchez LM; García-Sánchez SM; García-Ull J; Rubio-Flores L; Gonzalez-Martinez A; Quintas S; Echavarría Íñiguez A; Gil Luque S; Castro-Sánchez MV; Adell Ortega V; García Alhama J; Berrocal-Izquierdo N; Belvís R; Díaz-Insa S; Pozo-Rosich P; Huerta-Villanueva M
    J Headache Pain; 2023 Jun; 24(1):63. PubMed ID: 37268904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis.
    Giri S; Tronvik E; Linde M; Pedersen SA; Hagen K
    Cephalalgia; 2023 Apr; 43(4):3331024231156922. PubMed ID: 36856015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes.
    Foster SA; Hoyt M; Ye W; Mason O; Ford JH
    Curr Med Res Opin; 2022 May; 38(5):653-660. PubMed ID: 34761723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study.
    Domínguez C; Vieites-Prado A; Pérez-Mato M; Sobrino T; Rodríguez-Osorio X; López A; Campos F; Martínez F; Castillo J; Leira R
    Headache; 2018 Jan; 58(1):78-87. PubMed ID: 29131327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-calcitonin gene-related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache.
    Kang SA; Govindarajan R
    Muscle Nerve; 2021 Apr; 63(4):563-567. PubMed ID: 33347632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world treatment patterns and healthcare resource utilization among migraine patients: a German claims database analysis.
    Gaul C; Seidel K; Heuck A; Silaidos C; Mrosowsky T; Eberhardt A; Fritz B; Jacob C
    J Med Econ; 2023; 26(1):667-678. PubMed ID: 37126606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
    Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
    Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Onabotulinumtoxin A (ONA-BoNT/A) in the treatment of chronic migraine.
    Domitrz I; Sławek J; Słowik A; Boczarska-Jedynak M; Stępień A; Rejdak K; Gierczyński J; Rożniecki J
    Neurol Neurochir Pol; 2022; 56(1):39-47. PubMed ID: 34477213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine.
    Cohen F; Armand C; Lipton RB; Vollbracht S
    Pain Med; 2021 Aug; 22(8):1857-1863. PubMed ID: 33693863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of chronic migraine with intramuscular pericranial injections of onabotulinumtoxin a.
    Belvis R; Mas N
    Recent Pat CNS Drug Discov; 2014; 9(3):181-92. PubMed ID: 25643127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis.
    Drellia K; Kokoti L; Deligianni CI; Papadopoulos D; Mitsikostas DD
    Cephalalgia; 2021 Jun; 41(7):851-864. PubMed ID: 33567891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study.
    Barbanti P; Egeo G; Aurilia C; Torelli P; Finocchi C; d'Onofrio F; d'Onofrio L; Rao R; Messina S; Di Clemente L; Ranieri A; Autunno M; Sette G; Colombo B; Carnevale A; Aguggia M; Tasillo M; Zoroddu F; Frediani F; Filippi M; Tomino C; Proietti S; Bonassi S;
    J Headache Pain; 2023 Mar; 24(1):30. PubMed ID: 36949388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.